PMCPA
Novo Nordisk UK appoints George Godfrey as Senior Director, Medical & Regulatory
Godfrey previously served as Head of Medical for Respiratory and Immunology for AstraZeneca UK
New benchmark reveals significant digital maturity gap across UK POM companies’ product-information estates
A new benchmark maps 100 UK prescription medicine companies across five maturity bands and finds a market at very different stages of digital development
Why pharma website projects stall long before compliance becomes the problem
Pharma teams often blame compliance when digital projects slow down. In reality, the bigger issue is usually weaker ownership, unclear review models and content structures that were never designed for...
Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes
The insulin is designed as an alternative to daily basal insulin
Novo Nordisk elects employee representatives to Board of Directors
The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026
Novo Nordisk to invest 432m euros to expand manufacturing facility in Ireland
Construction is expected to be completed in phases from the end of 2027 into 2028
Novo Nordisk and Vivtex partner in deal worth up to $2.1bn
The companies aim to develop next-generation oral medicines for obesity and diabetes
Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic
The reduction in price to $675 will take effect at the beginning of next year
Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research
The companies are working together on cellular medicines to boost, replace or repair biological functions
Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity
Obesity affects approximately 15 million people in the UK
Novo Nordisk’s Wegovy approved by FDA as oral medication for weight management
Those taking the 25mg pill lost a similar amount of weight as those using injectable Wegovy 2.4mg
Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease
While the trials did not meet their primary endpoints, they highlighted important biomarker findings